Dubé Karine, Perry Kelly E, Mathur Kushagra, Lo Megan, Javadi Sogol S, Patel Hursch, Concha-Garcia Susanna, Taylor Jeff, Kaytes Andy, Dee Lynda, Campbell Danielle, Kanazawa John, Smith David, Gianella Sara, Auerbach Judith D, Saberi Parya, Sauceda John A
University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC, USA.
University of California San Diego (UCSD) School of Medicine, San Diego, CA, USA.
J Virus Erad. 2020 Aug 25;6(4):100008. doi: 10.1016/j.jve.2020.100008. eCollection 2020 Nov.
The question of what motivates people to participate in research is particularly salient in the HIV field. While participation in HIV research was driven by survival in the 1980's and early 1990's, access to novel therapies became the primary motivator with the advent of combination antiretroviral therapy (cART) in the late 1990s. In the HIV cure-related research context, the concept of altruism has remained insufficiently studied.
We conducted a scoping review to better contextualize and understand how altruism is or could be operationalized in HIV cure-related research. We drew from the fields of altruism in general, clinical research, cancer, and HIV clinical research-including the HIV prevention, treatment, and cure-related research fields.
Altruism as a key motivating factor for participation in clinical research has often been intertwined with the desire for personal benefit. The cancer field informs us that reasons for participation usually are multi-faceted and complex. The HIV prevention field offers ways to organize altruism-either by the types of benefits achieved (e.g., societal versus personal), or the origin of the values that motivate research participation. The HIV treatment literature reveals the critical role of clinical interactions in fostering altruism. There remains a dearth of in-depth knowledge regarding reasons surrounding research participation and the types of altruism displayed in HIV cure-related clinical research.
Lessons learned from various research fields can guide questions which will inform the assessment of altruism in future HIV cure-related research.
在艾滋病领域,是什么促使人们参与研究这一问题尤为突出。在20世纪80年代和90年代初,参与艾滋病研究是出于生存需求,而随着20世纪90年代末联合抗逆转录病毒疗法(cART)的出现,获得新型疗法成为了主要动机。在与艾滋病治愈相关的研究背景下,利他主义的概念仍未得到充分研究。
我们进行了一项范围综述,以便更好地将利他主义在与艾滋病治愈相关研究中如何或可能如何得以实施置于具体情境中并加以理解。我们借鉴了一般利他主义领域、临床研究、癌症以及艾滋病临床研究领域——包括艾滋病预防、治疗和与治愈相关的研究领域。
利他主义作为参与临床研究的关键动机因素,常常与个人利益诉求交织在一起。癌症领域告诉我们,参与的原因通常是多方面且复杂的。艾滋病预防领域提供了组织利他主义的方式——要么依据所获得利益的类型(例如,社会利益与个人利益),要么依据促使参与研究的价值观的来源。艾滋病治疗文献揭示了临床互动在培养利他主义方面的关键作用。在与艾滋病治愈相关的临床研究中,关于参与研究的原因以及所展现的利他主义类型,仍然缺乏深入的了解。
从各个研究领域吸取的经验教训可以指导相关问题,这些问题将为未来与艾滋病治愈相关研究中的利他主义评估提供参考。